Home / Market News / $LABT

$LABT news and market catalysts

The 4 most recent market catalysts affecting $LABT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

4 catalysts 0 high impact 4 bullish 0 bearish Biotechnology
Oct 21, 2026 Corporate Catalyst Bullish Impact 65
Lakewood-Amedex Biotherapeutics Presents Research Highlighting Antimicrobial Profile Of Nu-3, Lead Clinical Candidate, At IDWeek 2026; Topline Data From Trial Expected In Q1 2027
Lakewood-Amedex Biotherapeutics (LABT) announced the presentation of research on its lead clinical candidate, Nu-3, at IDWeek 2026. The research highlights Nu-3's rapid and broad-s…
Oct 7, 2026 Corporate Catalyst Bullish Impact 75
LABT stock has given up its prior gain. Lakewood-Amedex Biotherapeutics shares were trading higher after the company announced preclinical data in UTI and pulmonary infection indications in animal models treated with Bisphosphocin compounds.
The headline indicates a significant corporate catalyst for Lakewood-Amedex Biotherapeutics (LABT). Positive preclinical data in animal models for Bisphosphocin compounds in UTI an…
Sep 28, 2026 Corporate Catalyst Bullish Impact 65
Lakewood-Amedex Biotherapeutics Announces Minimum Inhibitory Concentration Data From Recent Clinical Isolates Of Nu-3 Demonstrates Consistent Activity Against All Organisms
Lakewood-Amedex Biotherapeutics (LABT) reported positive MIC data for its antimicrobial candidate, Nu-3, showing consistent activity against various clinical isolates and a strong …
Jul 22, 2026 Corporate Catalyst Bullish Impact 65
Lakewood-Amedex Biotherapeutics Announces Resistance Data For Nu-3 In Alignment With Presidential Advisory Council On Combating Antibiotic Resistant Bacteria
Lakewood-Amedex Biotherapeutics (LABT) announced that resistance data for its drug candidate, Nu-3, aligns with the Presidential Advisory Council on Combating Antibiotic Resistant …
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.